High TWIST1 MRNA Expression is Associated with Poor Prognosis in Lymph Node-negative and Estrogen Receptor-positive Human Breast Cancer and is Co-expressed with Stromal As Well As ECM Related Genes

Overview

Journal Breast Cancer Res

Specialty Oncology

Date 2012 Sep 13

PMID 22967435

Citations 25

Authors

Muhammad Riaz

Anieta M Sieuwerts

Maxime P Look

Mieke A Timmermans

Marcel Smid

John A Foekens

John W M Martens

Affiliations

Soon will be listed here.

Abstract

Introduction: The TWIST homolog 1 (TWIST1) is a transcription factor that induces epithelial to mesenchymal transition (EMT), a key process in metastasis. The purpose of this study was to investigate whether TWIST1 expression predicts disease progression in a large breast cancer cohort with long-term clinical follow-up, and to reveal the biology related to TWIST1 mediated disease progression.

Methods: TWIST1 mRNA expression level was analyzed by quantitative real-time reverse polymerase chain reaction (RT-PCR) in 1,427 primary breast cancers. In uni- and multivariate analysis using Cox regression, TWIST1 mRNA expression level was associated with metastasis-free survival (MFS), disease-free survival (DFS) and overall survival (OS). Separate analyses in lymph node-negative patients (LNN, n = 778) who did not receive adjuvant systemic therapy, before and after stratification into estrogen receptor (ER)-positive (n = 552) and ER-negative (n = 226) disease, were also performed. The association of TWIST1 mRNA with survival endpoints was assessed using Kaplan-Meier analysis. Using gene expression arrays, genes showing a significant Spearman rank correlation with TWIST1 were used to identify overrepresented Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG)-annotated biological pathways.

Results: Increased mRNA expression level of TWIST1 analyzed as a continuous variable in both uni- and multivariate analysis was associated with shorter MFS in all patients (hazard ratio (HR): 1.17, 95% confidence interval, (95% CI):1.09 to 1.26; and HR: 1.17, 95% CI: 1.08 to 1.26; respectively), in LNN patients (HR: 1.22, 95% CI: 1.09 to 1.36; and HR: 1.21, 95% CI: 1.07 to 1.36; respectively) and in the ER-positive subgroup of LNN patients (HR: 1.34, 95% CI: 1.17 to 1.53; and HR: 1.32, 95% CI: 1.14 to 1.53; respectively). Similarly, high TWIST1 expression was associated with shorter DFS and OS in all patients and in the LNN/ER-positive subgroup. In contrast, no association of TWIST1 mRNA expression with MFS, DFS or OS was observed in ER-negative patients. Genes highly correlated with TWIST1 were significantly enriched for cell adhesion and ECM-related signaling pathways. Furthermore, TWIST1 mRNA was highly expressed in tumor stroma and positively related to tumor stromal content (P <0.001).

Conclusions: TWIST1 mRNA expression is an independent prognostic factor for poor prognosis in LNN/ER-positive breast cancer. The biological associations suggest an involvement of the tumor microenvironment in TWIST1's adverse role in breast cancer.

Citing Articles

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition.

Glaviano A, Lau H, Carter L, Lee E, Lam H, Okina E J Hematol Oncol. 2025; 18(1):6.

PMID: 39806516 PMC: 11733683. DOI: 10.1186/s13045-024-01634-6.

Tumor-Agnostic Therapy-The Final Step Forward in the Cure for Human Neoplasms?.

El-Sayed M, Bianco J, Li Y, Fabian Z Cells. 2024; 13(12.

PMID: 38920700 PMC: 11201516. DOI: 10.3390/cells13121071.

Benzophenone-3 alters expression of genes encoding vascularization and epithelial-mesenchymal transition functions during Trp53-null mammary tumorigenesis.

Morozova E, Kariagina A, Busch C, Schwartz R Food Chem Toxicol. 2024; 186:114540.

PMID: 38387520 PMC: 10978255. DOI: 10.1016/j.fct.2024.114540.

Molecular mechanisms of TWIST1-regulated transcription in EMT and cancer metastasis.

Yu X, He T, Tong Z, Liao L, Huang S, Fakhouri W EMBO Rep. 2023; 24(11):e56902.

PMID: 37680145 PMC: 10626429. DOI: 10.15252/embr.202356902.

Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment.

Anderle N, Schafer-Ruoff F, Staebler A, Kersten N, Koch A, Onder C J Exp Clin Cancer Res. 2023; 42(1):210.

PMID: 37596623 PMC: 10436441. DOI: 10.1186/s13046-023-02782-2.

References

Umar A, Dalebout J, Timmermans A, Foekens J, Luider T . Method optimisation for peptide profiling of microdissected breast carcinoma tissue by matrix-assisted laser desorption/ionisation-time of flight and matrix-assisted laser desorption/ionisation-time of flight/time of flight-mass spectrometry. Proteomics. 2005; 5(10):2680-8. DOI: 10.1002/pmic.200400128. View

Firulli A, Conway S . Phosphoregulation of Twist1 provides a mechanism of cell fate control. Curr Med Chem. 2008; 15(25):2641-7. PMC: 2744367. DOI: 10.2174/092986708785908987. View

Blick T, Widodo E, Hugo H, Waltham M, Lenburg M, Neve R . Epithelial mesenchymal transition traits in human breast cancer cell lines. Clin Exp Metastasis. 2008; 25(6):629-42. DOI: 10.1007/s10585-008-9170-6. View

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100(2):229-35. DOI: 10.1007/s10549-006-9242-8. View

Ru G, Wang H, Xu W, Zhao Z . Upregulation of Twist in gastric carcinoma associated with tumor invasion and poor prognosis. Pathol Oncol Res. 2010; 17(2):341-7. DOI: 10.1007/s12253-010-9332-0. View

Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, Wirapati P . A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009; 15(1):68-74. DOI: 10.1038/nm.1908. View

Leptin M . twist and snail as positive and negative regulators during Drosophila mesoderm development. Genes Dev. 1991; 5(9):1568-76. DOI: 10.1101/gad.5.9.1568. View

Roman-Perez E, Casbas-Hernandez P, Pirone J, Rein J, Carey L, Lubet R . Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients. Breast Cancer Res. 2012; 14(2):R51. PMC: 3446385. DOI: 10.1186/bcr3152. View

Valsesia-Wittmann S, Magdeleine M, Dupasquier S, Garin E, Jallas A, Combaret V . Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell. 2004; 6(6):625-30. DOI: 10.1016/j.ccr.2004.09.033. View

10.

Sieuwerts A, Meijer-Van Gelder M, Timmermans M, Trapman A, Rodriguez Garcia R, Arnold M . How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res. 2005; 11(20):7311-21. DOI: 10.1158/1078-0432.CCR-05-0560. View

11.

Soini Y, Tuhkanen H, Sironen R, Virtanen I, Kataja V, Auvinen P . Transcription factors zeb1, twist and snai1 in breast carcinoma. BMC Cancer. 2011; 11:73. PMC: 3055233. DOI: 10.1186/1471-2407-11-73. View

12.

Elias M, Tozer K, Silber J, Mikheeva S, Deng M, Morrison R . TWIST is expressed in human gliomas and promotes invasion. Neoplasia. 2005; 7(9):824-37. PMC: 1501937. DOI: 10.1593/neo.04352. View

13.

Valdes-Mora F, Gomez del Pulgar T, Bandres E, Cejas P, Ramirez de Molina A, Perez-Palacios R . TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer. Ann Surg Oncol. 2008; 16(1):78-87. DOI: 10.1245/s10434-008-0166-x. View

14.

Tong W, Cao X, Harris S, Sun H, Fang H, Fuscoe J . ArrayTrack--supporting toxicogenomic research at the U.S. Food and Drug Administration National Center for Toxicological Research. Environ Health Perspect. 2003; 111(15):1819-26. PMC: 1241745. DOI: 10.1289/ehp.6497. View

15.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

16.

Okada T, Suehiro Y, Ueno K, Mitomori S, Kaneko S, Nishioka M . TWIST1 hypermethylation is observed frequently in colorectal tumors and its overexpression is associated with unfavorable outcomes in patients with colorectal cancer. Genes Chromosomes Cancer. 2010; 49(5):452-62. DOI: 10.1002/gcc.20755. View

17.

Sieuwerts A, Usher P, Meijer-Van Gelder M, Timmermans M, Martens J, Brunner N . Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. Clin Chem. 2007; 53(7):1280-8. DOI: 10.1373/clinchem.2006.082800. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Fondrevelle M, Kantelip B, Reiter R, Chopin D, Thiery J, Monnien F . The expression of Twist has an impact on survival in human bladder cancer and is influenced by the smoking status. Urol Oncol. 2008; 27(3):268-76. DOI: 10.1016/j.urolonc.2007.12.012. View

20.

Kress W, Schropp C, Lieb G, Petersen B, Busse-Ratzka M, Kunz J . Saethre-Chotzen syndrome caused by TWIST 1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome. Eur J Hum Genet. 2005; 14(1):39-48. DOI: 10.1038/sj.ejhg.5201507. View